Severe cutaneous adverse reaction following COVID-19 vaccination and immunotherapy: a second hit?

Hussain, K; Kawsar, A; Weir, J; Au, L; Turajlic, S; Larkin, J; Fearfield, L

Hussain, K; Kawsar, A; Weir, J; Au, L; Turajlic, S; Larkin, J; Fearfield, L.

Hussain K; Department of Dermatology, Chelsea and Westminster Hospital, London, UK.
Kawsar A; Department of Dermatology, Chelsea and Westminster Hospital, London, UK.
Weir J; Department of Histopathology, Imperial College Healthcare NHS Trust, London, UK.
Au L; Skin and Melanoma Unit, Royal Marsden Hospital, London, UK.
Turajlic S; Skin and Melanoma Unit, Royal Marsden Hospital, London, UK.
Larkin J; Skin and Melanoma Unit, Royal Marsden Hospital, London, UK.
Fearfield L; Department of Dermatology, Chelsea and Westminster Hospital, London, UK.

Clin Exp Dermatol ; 47(1): 149-151, 2022 01.

Article in English | MEDLINE | ID: covidwho-1356836

Subject(s)

BNT162 Vaccine/adverse effects; Drug Eruptions/diagnosis; Drug Eruptions/etiology; Immune Checkpoint Inhibitors/adverse effects; Ipilimumab/adverse effects; Nivolumab/adverse effects; Anti-Bacterial Agents/adverse effects; COVID-19/prevention & control; Female; Humans; Melanoma/drug therapy; Middle Aged; Trimethoprim, Sulfamethoxazole Drug Combination/adverse effects

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Drug Eruptions / Ipilimumab / Nivolumab / Immune Checkpoint Inhibitors / BNT162 Vaccine Type of study: Case report / Diagnostic study Topics: Vaccines Limits: Female / Humans / Middle aged Language: English Journal: Clin Exp Dermatol Year: 2022 Document Type: Article Affiliation country: Ced.14852

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google